Management of malignant pleural effusions: Questions that need answers

Current Opinion in Pulmonary Medicine

Volumn 19, Issue 4, 2013, Pages 374-379

  Davies, Helen E ^a   Lee, Y C Gary ^b,c  

^a UNIVERSITY HOSPITAL OF WALES   (United Kingdom)

^b Department of Physiotherapy Charles Gairdner Hospital   (Australia)

^c UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

indwelling pleural catheter; mesothelioma; pleural effusion; pleurodesis; talc

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; MONOCYTE CHEMOTACTIC PROTEIN 1; OSTEOPONTIN; TALC; VASCULOTROPIN; ZOLEDRONIC ACID;

DISEASE COURSE; DISEASE EXACERBATION; DYSPNEA; HUMAN; INCIDENCE; INDWELLING CATHETER; LUNG ADENOCARCINOMA; MALIGNANT PLEURAL EFFUSION; NONHUMAN; OUTCOME ASSESSMENT; PATIENT CARE; PATIENT SELECTION; PLEURA CAVITY; PLEURA EFFUSION; PLEURA FLUID; PLEURA MESOTHELIOMA; PLEURAL CATHETER; PLEURAL FIBROSIS; PLEURODESIS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; VISUAL ANALOG SCALE;

CATHETERIZATION; CATHETERS, INDWELLING; COST-BENEFIT ANALYSIS; DECISION MAKING; DRAINAGE; FEMALE; HUMANS; MALE; PLEURAL EFFUSION, MALIGNANT; PLEURODESIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SCLEROSING SOLUTIONS; SURVIVAL RATE; TALC; TREATMENT OUTCOME;

EID: 84879895063     PISSN: 10705287     EISSN: 15316971     Source Type: Journal    
DOI: 10.1097/MCP.0b013e3283615b67     Document Type: Review

References (35)

1. Mishra EK, Davies HE, Lee YCG. Malignant pleural disease in primary lung cancer. In: Spiro SG, Janes SM, editors. Thoracic malignancies. European respiratory monograph. Sheffield, UK: European Respiratory Society Journals Ltd; 2009. pp. 318-335.
2. West SD, Lee YC. Management of malignant pleural mesothelioma. Clin Chest Med 2006; 27:335-354.
3. Le GV, Takahashi K, Park E-K, et al. Asbestos use and asbestos-related diseases in Asia: past, present and future. Respirology 2011; 16:767-775.
4. Bethune N. Pleural poudrage: new technique for the deliberate production of pleural adhesion as preliminary to lobectomy. J Thorac Surg 1935; 4., /
5. Marel M, Zrustová M, Stasný B, Light RW. The incidence of pleural effusion in a well defined region. Epidemiologic study in central Bohemia. Chest 1993; 104:1486-1489.
6. Peacock AJ, Murphy NF, McMurray JJ, et al. An epidemiological study of pulmonary arterial hypertension. Eur Respir J 2007; 30:104-109.
7. Davies HE, Lee YC, Davies RJ. Pleurodesis for malignant pleural effusion: talc, toxicity and where next? Thorax 2008; 63:572-574.
8. Maskell NA, Lee YC, Gleeson FV, et al. Randomized trials describing lung inflammation after pleurodesis with talc of varying particle size. Am J Respir Crit Care Med 2004; 170:377-382.
9. Stathopoulos GT, Kalomenidis I. Malignant pleural effusion: tumor-host interactions unleashed. Am J Respir Crit Care Med 2012; 186:487-492.
10. Fysh ET, Tan SK, Read CA, et al. Pleurodesis outcome in malignant pleural mesothelioma. Thorax 2013. doi: 10.1136/thoraxjnl-2012-203043.[Epub ahead of print]
11. Lee YCG, Light RW. Pleural effusion: overview. In: Laurent GJ, Shapiro S, editors. Encyclopedia of respiratory diseases, 4th ed. Oxford, UK: Elsevier; 2006. pp. 353-358.
12. Chiumello D, Marino A, Cressoni M, et al. Pleural effusion in patients with acute lung injury. Crit Care Med 2013; 41:935-944.
13. Doelken P, Abreu R, Sahn SA, Mayo PH. Effect of thoracentesis on respiratory mechanics and gas exchange in the patient receiving mechanical ventilation. Chest 2006; 130:1354-1361.
14. Wang LM, Cherng JM, Wang JS. Improved lung function after thoracocentesis in patients with paradoxical movement of a hemidiaphragm secondary to a large pleural effusion. Respirology 2007; 12:719-723.
15. Mulvey RB. The effect of pleural fluid on the diaphragm. Radiology 1965; 84:1080-1086.
16. Dresler CM, Olak J, Herndon JE 2nd, et al. Phase III intergroup study of talc poudrage vs talc slurry sclerosis for malignant pleural effusion. Chest 2005; 127:909-915.
17. American Thoracic Society. Management of malignant pleural effusions. Am J Respir Crit Care Med 2000; 162:1987-2001.
18. Davies HE, Mishra EK, Kahan BC, et al. Effect of an indwelling pleural catheter vs chest tube and talc pleurodesis for relieving dyspnea in patients with malignant pleural effusion: the TIME2 randomized controlled trial. JAMA 2012; 307:2383-2389.
19. Heffner JE, Nietert PJ, Barbieri C. Pleural fluid pH as a predictor of survival for patients with malignant pleural effusions. Chest 2000; 117:79-86.
20. Fysh ET, Waterer GW, Kendall PA, et al. Indwelling pleural catheters reduce inpatient days over pleurodesis for malignant pleural effusion. Chest 2012; 142:394-400.
21. Lee YC, Light RW. Management of malignant pleural effusions. Respirology 2004; 9:148-156.
22. Weissberg D, Ben-Zeev I. Talc pleurodesis. Experience with 360 patients. J Thorac Cardiovasc Surg 1993; 106:689-695.
23. Terra RM, Junqueira JJ, Teixeira LR, et al. Is full postpleurodesis lung expansion a determinant of a successful outcome after talc pleurodesis? Chest 2009; 136:361-368.
24. Yim AP, Chan AT, Lee TW, et al. Thoracoscopic talc insufflation versus talc slurry for symptomatic malignant pleural effusion. Ann Thorac Surg 1996; 62:1655-1658.
25. Lee YC, Baumann MH, Maskell NA, et al. Pleurodesis practice for malignant pleural effusions in five English-speaking countries: survey of pulmonologists. Chest 2003; 124:2229-2238.
26. Crnjac A, Sok M, Kamenik M. Impact of pleural effusion pH on the efficacy of thoracoscopic mechanical pleurodesis in patients with breast carcinoma. Eur J Cardiothorac Surg 2004; 26:432-436.
27. Putnam JB Jr, Light RW, Rodriguez RM, et al. A randomized comparison of indwelling pleural catheter and doxycycline pleurodesis in the management of malignant pleural effusions. Cancer 1999; 86:1992-1999.
28. Wrightson JM, Fysh E, Maskell NA, Lee YC. Risk reduction in pleural procedures: sonography, simulation and supervision. Curr Opin Pulm Med 2010; 16:340-350.
29. Janes SM, Rahman NM, Davies RJ, Lee YC. Catheter-tract metastases associated with chronic indwelling pleural catheters. Chest 2007; 131: 1232-1234.
30. Tremblay A, Mason C, Michaud G. Use of tunnelled catheters for malignant pleural effusions in patients fit for pleurodesis. Eur Respir J 2007; 30:759-762.
31. Puri V, Pyrdeck TL, Crabtree TD, et al. Treatment of malignant pleural effusion: a cost-effectiveness analysis. Ann Thorac Surg 2012; 94:374-379; discussion 379-380.
32. Lee YC, Fysh ET. Indwelling pleural catheter: changing the paradigm of malignant effusion management. J Thorac Oncol 2011; 6:655-657.
33. Grove CS, Lee YC. Vascular endothelial growth factor: the key mediator in pleural effusion formation. Curr Opin Pulm Med 2002; 8:294-301.
34. Maskell NA. A double blind randomised controlled trial examining the effect of intravenous zoledronic acid on pleural fluid production, breathlessness and quality of life in patients with a malignant pleural effusion. 2013. http:// public.ukcrn.org.uk/search/StudyDetail.aspx?StudyID8877.
35. Han HS, Eom DW, Kim JH, et al. EGFR mutation status in primary lung adenocarcinomas and corresponding metastatic lesions: discordance in pleural metastases. Clin Lung Cancer 2011; 12:380-386.